These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29137059)

  • 1. Adherence to gout management recommendations of Chinese patients.
    Sheng F; Fang W; Zhang B; Sha Y; Zeng X
    Medicine (Baltimore); 2017 Nov; 96(45):e8532. PubMed ID: 29137059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
    Hu S; Terkeltaub R; Sun M; Ji X; Li Z; Ran Z; Li Y; Zhang H; Sun W; Li C; Lu J
    Joint Bone Spine; 2022 Nov; 89(6):105435. PubMed ID: 35777552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.
    Yin R; Cao H; Fu T; Zhang Q; Zhang L; Li L; Gu Z
    Rheumatol Int; 2017 Jul; 37(7):1187-1194. PubMed ID: 28551724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting.
    Lee S; So MW
    Mod Rheumatol; 2016 Nov; 26(6):950-955. PubMed ID: 27142782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and Treat-to-Target Benchmarks in Older Adults With Gout Initiating Urate-Lowering Therapy in Ontario, Canada: A Population-Based Study.
    Kwok TSH; Kuriya B; Hawker G; Eder L; Li P; Choy G; Widdifield J
    Arthritis Care Res (Hoboken); 2024 Oct; 76(10):1379-1389. PubMed ID: 38831665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between patient adherence and treat-to-target in gout: A cross-sectional study.
    Hu S; He S; Zhang J; Ma W; Geng H; Zhan Z; Yao X; Zhong L; Wei J; Qiu X; Jia E
    Medicine (Baltimore); 2024 Feb; 103(8):e37228. PubMed ID: 38394537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
    Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR
    J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada.
    Kwok TSH; Kuriya B; Hawker G; Li P; Choy G; Widdifield J
    Arthritis Care Res (Hoboken); 2023 Dec; 75(12):2463-2471. PubMed ID: 37248652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric evaluation of the Adherence to Refills and Medications Scale (ARMS) in Australians living with gout.
    Schulz M; Day RO; Coleshill MJ; Briggs NE; Aung E
    Clin Rheumatol; 2024 Sep; 43(9):2943-2954. PubMed ID: 39008222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication adherence among patients with gout: A systematic review and meta-analysis.
    Scheepers LEJM; van Onna M; Stehouwer CDA; Singh JA; Arts ICW; Boonen A
    Semin Arthritis Rheum; 2018 Apr; 47(5):689-702. PubMed ID: 29198878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study.
    Singh JA
    Arthritis Res Ther; 2014 Mar; 16(2):R82. PubMed ID: 24678765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
    Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
    Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden and management of gout in a multi-ethnic Asian cohort.
    Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
    Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
    Huang IJ; Liew JW; Morcos MB; Zuo S; Crawford C; Bays AM
    Rheumatol Int; 2019 Sep; 39(9):1637-1641. PubMed ID: 31147732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
    Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
    Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive dietary education in treated gout patients does not further improve serum urate.
    Holland R; McGill NW
    Intern Med J; 2015 Feb; 45(2):189-94. PubMed ID: 25495503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
    Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
    Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gout, urate-lowering therapy, and uric acid levels among adults in the United States.
    Juraschek SP; Kovell LC; Miller ER; Gelber AC
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):588-92. PubMed ID: 25201123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.